

UNCLASSIFIED

AD NUMBER
ADB264450
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Jul 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702-5012
AUTHORITY
USAMRMC ltr, 26 Nov 2002

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-99-1-9511

TITLE: Characterization of a Novel Apoptosis Regulator BI-1

PRINCIPAL INVESTIGATOR: Ning Ke, Ph.D.

CONTRACTING ORGANIZATION: The Burnham Institute
La Jolla, California 92037

REPORT DATE: July 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Jul 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010322 158

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9511
Organization: The Burnham Institute
Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Nimisha Chandra Mirm
02/15/07

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2000		3. REPORT TYPE AND DATES COVERED Annual Summary (1 Jul 99 - 30 Jun 00)
4. TITLE AND SUBTITLE Characterization of a Novel Apoptosis Regulator BI-1			5. FUNDING NUMBERS DAMD17-99-1-9511	
6. AUTHOR(S) Ning Ke, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Burnham Institute La Jolla, California 92037 E-MAIL: nke@burnham-inst.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Jul 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) BI-1 is an important cell death regulator that protects cells against Bax-induced cell death. It is expressed in all four prostate cancer lines and overexpressed in two of them, making it an important regulator in prostate cancer progression. I have used genetics, biochemical and cell biology approaches to understand how BI-1 regulate apoptosis and possibly prostate cancer. I have demonstrated the in vivo function of BI-1 homolog in yeast; I have discovered that BI-1 homologs from different species, including plant, fly, yeast and E. coli can function similarly in yeast to protect Bax-induced cell death. I have also mapped important BI-1 domains essential for its function. These provide the basis for understanding the mechanism through which BI-1 regulates apoptosis.				
14. SUBJECT TERMS Prostate Cancer			15. NUMBER OF PAGES 8	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

N/A Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

8/1/00

Date

Table of Contents

Cover.....	
SF 298.....	2
Foreword.....	3
Table of Contents.....	4
Introduction.....	5
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	
Conclusions.....	7
References.....	
Appendices.....	

Introduction:

BI-1 is a novel anti-apoptotic regulator identified in our lab through the Bax suppressor screen conducted in yeast. Its anti-apoptotic function in mammalian cells makes it a possible regulator for cancer progression. BI-1 is expressed in all four prostate cancer cell lines tested and highly expressed in two of them, thus makes it a potential target for prostate cancer therapy. We have proposed to use genetics, cell biology and biochemistry approaches to study the structure and function of this novel apoptotic regulator and its potential function in prostate cancers.

Body:

I have focused my first year's training on studying the in vivo function of BI-1 and the structural and functional analysis of BI-1. Several important findings have been made that are described below:

I have successfully identified and demonstrated the function of the potential yeast BI-1 homolog. The yeast BI-1 homolog (yBI-1) was identified through blast search of the yeast genome database against BI-1 sequence. The yBI-1 was not an essential gene and its knock-out yeast strain was therefore obtained and characterized. Because of the protective nature of BI-1, I have tested the function of y-BI-1 against stress-induced cell death. Interestingly, I have found that the surviving ability of yBI-1 deletion strain is much lower compared to wild-type strain, suggesting that yBI-1 is important for protecting yeast cells from heat. Along with this observation, it is recently published that the Arabidopsis BI-1 homolog can be induced by wound and pathogen challenge, further extending that BI-1 is an evolutionarily conserved protein with cell protective function.

More interestingly, overexpression of the yBI-1 gene can suppress Bax-induced cell death in yeast, indicating it is a functional BI-1 homolog. Besides, I have also obtained the putative BI-1 homologs from plants (Arabidopsis, Rice and Tomato), Drosophila and bacteria. Overexpression of all these BI-1 genes rescued the yeast cells from Bax-induced cell death. Therefore, BI-1 appears to be an evolutionarily conserved protective protein present throughout the prokaryotic and eukaryotic kingdom.

Discovery of BI-1 homologs makes it possible to identify potential important BI-1 domains by aligning the homologs and identifying important residues. BI-1 is a membrane protein with six transmembrane domains. Two regions are initially identified through the alignment, with one at the 3' cytosolic end and the other between the last two transmembrane domain. These two domains were mutated and tested for their function in yeast cells. While the one with mutation in the most c-terminal nine amino acids replaced with alanine abolished BI-1 protective function against Bax-induced cell death, the other doesn't show any phenotype. Besides these two mutations, deletion analysis of BI-1 gene was also carried out to identify important domains essential for its function. Thirteen BI-1 deletion mutants were constructed so that each mutant has deletion in each of the TM domain or domain between the two adjacent TM domains. These mutants were then tested for their function in the yeast cells to determine their protective function. All but two of deletion constructs can still rescue yeast from the Bax-induced cell death,

and these two deletions are located at the N-terminal cytosolic domain and the region between TM1 and TM2. Thus, it appears that all six TM domains are essential for BI-1 function. Interestingly, deletion or mutation of the most c-terminal nine amino acids into alanine also changed the cellular localization of BI-1 protein, therefore indicating that these nine amino acids are essential for BI-1 function and localization. These mutants will provide us with the necessary tool for dissecting BI-1 structure and function.

Besides working on BI-1 gene, I have screened five more cDNA libraries in order to identify new Bax-suppressors in yeast. These screens have yielded known apoptosis regulator genes such as Bcl-2, Bcl-Xl, Mcl-1, BI-1 and BI-1 homologs, suggesting that the yeast assay is an important system to identify apoptosis regulators. More importantly, I have identified two new genes that can rescue the yeast cells from Bax-induced cell death. I am currently characterizing their functions in mammalian cells. At the meantime, I also started to work on another important gene, BI-2 (BAR), that is identified in the same screen when BI-1 is identified. BAR protects mammalian cells against both the Bax- and Fas- induced cell death, that are the two major cell death pathway. Most interestingly, BAR is overexpressed in many tumor cell lines, thus making it an interesting regulator for tumor progression. Through analysis of these Bax-inhibitor proteins, we will be able to better understand the functions of Bax and its inhibitors.

Work in progress:

In addition to the work described above, some experiments in progress below are described below:

BI-1 homolog in mice has also been identified. Its knockout cell line is identified in the Lexcon database. The Knock-out BI-1 mice has been ordered. Upon receipt, phenotypes will be determined. This will tell us ultimately the in vivo function of BI-1 gene. At the meantime, BI-1 antibody is being raised against a BI-1 peptide. The successful antibody will allow us to test the expression of BI-1 in the prostate cancer cell lines to correlate the BI-1 expression and different prostate cancer specimen.

Expression of the BI-1 homologs will also be conducted in mammalian cells to determine whether they function similarly to the yeast cells. The functions of various BI-1 mutant described above will also be tested in mammalian cells to determine the ultimate important BI-1 domains involved in apoptosis regulation. These study will provide us the basis for understanding BI-1's structure and function and its possible role in prostate cancer progression.

Key research accomplishments:

Demonstrated yeast BI-1 homolog's function in stress-induced cell death.

Demonstrated BI-1 homologs' function in protecting yeast cells against Bax-induced cell death.

Identified several BI-1 domains essential for its protective function.

Discovered two more genes that can protect the yeast against Bax-induced cell death.

Reportable outcomes:

N/A.

Conclusions:

In conclusion, I have made a lot of progress toward understanding the mechanisms by which BI-1 regulate apoptosis: namely, the identification of BI-1 homologs from various species and their similar protective functions; and the identification of BI-1 domains essential for its function. These will provide basis for BI-1's structural and functional analysis. The mouse knock-out study will definitely demonstrate BI-1 in vivo function, while the development will determine whether there are any correlation between BI-1 expression and prostate cancer. These studies will help us better understand BI-1's function and its possible role in prostate cancers.



DEPARTMENT OF THE ARMY

US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

26 Nov 02

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLLIS M. PINEHART
Deputy Chief of Staff for
Information Management

ADB263708
ADB257291
ADB262612
ADB266082
ADB282187
ADB263424
ADB267958
ADB282194
ADB261109
ADB274630
ADB244697
ADB282244
ADB265964
ADB248605
ADB278762
ADB264450
ADB279621
ADB261475
ADB279568
ADB262568
ADB266387
ADB279633
ADB266646
ADB258871
ADB266038
ADB258945
ADB278624